In a report released yesterday, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Aclaris Therapeutics Inc (ACRS), with a price target of $50. The company’s shares closed yesterday at $6.57, close to its 52-week low of $5.04.
Chen observed:
“: Post a solid 1Q19, and ahead of what we expect to be a catalyst-rich year for ACRS, we are reiterating our OW rating and 12-month PT of $50. We continue to recommend ACRS as one of our top ideas this year. ACRS’s valuation is inexpensive for a company with two commercial assets and multiple, potentially positive, data readouts. Therefore, we think upward earnings revisions to levels not yet reflected in consensus expectations should drive the stock higher.”
According to TipRanks.com, Chen is a 4-star analyst with an average return of 6.6% and a 38.6% success rate. Chen covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Bausch Health Companies Inc, and Amneal Pharmaceuticals Inc.
Aclaris Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $21.97 and a one-year low of $5.04. Currently, Aclaris Therapeutics Inc has an average volume of 547.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Dermatology Therapeutics and Contract Research segments.
